The MUC6 antibody targets MUC6. a secreted glycoprotein belonging to the mucin family, which plays critical roles in epithelial protection and lubrication. Encoded by the *MUC6* gene, this gel-forming mucin is characterized by tandem repeat domains rich in proline, threonine, and serine (PTS repeats) that undergo extensive O-glycosylation, contributing to its viscous properties. MUC6 is predominantly expressed in mucosal tissues, including the stomach, gallbladder, and pancreatic ducts, where it forms a protective barrier against mechanical stress, pathogens, and digestive enzymes. It also modulates immune responses and microbial interactions.
Aberrant MUC6 expression is linked to pathologies such as gastric cancer, ovarian cancer, and inflammatory gastrointestinal diseases. In cancer, MUC6 overexpression is associated with tumor progression and metastasis, though its role varies by tissue context. Antibodies against MUC6 are essential tools for studying its expression patterns, glycosylation status, and pathological implications. They are used in immunohistochemistry, ELISA, and Western blotting to diagnose malignancies, assess prognosis, or explore therapeutic targets. However, challenges remain due to MUC6's structural complexity, glycosylation heterogeneity, and cross-reactivity with other mucins. Ongoing research aims to refine antibody specificity and elucidate MUC6's dual roles in homeostasis and disease, offering potential for targeted therapies.